From: Neethling W, Rea A, Forster G and Bhirangi K (2020)...

From: Neethling W, Rea A, Forster G and Bhirangi K (2020) Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes. Front. Pediatr. 8:198. doi: 10.3389/fped.2020.00198

In addition, short to medium term retrospective studies with Cardiocel have also demonstrated positive outcomes in terms of performance, no calcification and efficacy (21–24).A less favorable outcome (freedom from reoperation 57% at 36 months) was reported in a single center study of CardioCel^® used in aortic valve reconstruction in young children (25). On the other hand, a more promising outcome was reported by Bell et al. (23) with freedom from reintervention in 135 patients (140 procedures and 195 implants) at 36 months of 94% (CI 89–97) without any evidence of calcification after echocardiographic and radiological assessment in any of these patients. Similar results were reported in a multi-center study (Brisbane, Australia; and Leicester and Bristol, United Kingdom) with an overall freedom from reintervention at 3 and 5 years after implantation of 96% (95% confidence interval, 93–98%) (24).

25. Nordmeyer S, Murin P, Schulz A, Danne F, Nordmeyer J, Kretzschmar J, et al. Results of aortic valve repair using decellularized bovine pericardium in congenital surgery. Eur J Cardiothorac Surg. (2018) 54:986–92. doi: 10.1093/ejcts/ezy181